1. Pink Sheet
  2. >>Pathways & Standards

Australia Seeks Views On Revised National Medicines Policy

 
• By Ian Schofield

As part of its ongoing review of the National Medicines Policy, Australia’s Department of Health calls for “robust and transparent prioritization of spending on medicines” as well as a collective approach to ensuring speedy and equitable access to affordable medicines for all communities.

Australia map with medicines capsules
Australia's medicines policy is being updated • Source: Alamy

The Australian government is seeking feedback on an updated version of its National Medicines Policy, which proposes to create an environment that allows drugs to be accessible “in an equitable, safe, timely, and affordable way and to be used optimally according to the principles of person-centered care and the quality use of medicines.”

The consultation document outlines a governance and evaluation approach that acknowledges that the success of the NMP “is dependent on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 
• By Bridget Silverman

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.

US FDA’s CoGenT Pilot At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 
• By Bridget Silverman

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.